Acetylcholinesterase (AChE) inhibitors, such as donepezil and rivastigmine, NMDA receptor antagonists, and memantine, are licensed for AD treatment; however, they provide limited symptomatic benefits [31]. The gene discussed is ACHE; the disease is Alzheimer disease.